Stockreport

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Develo...

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral [Read more]